Michael A. Morse
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
- Immunology top 0.2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 184
- Cancer Immunotherapy and Biomarkers 78
- Colorectal Cancer Treatments and Studies 38
- CAR-T cell therapy research 29
- Immunology 135
- Immunotherapy and Immune Responses 118
- Immune Cell Function and Interaction 30
- T-cell and B-cell Immunology 25
- Co-authors
- H. Kim Lyerly (145 shared papers)Timothy M. Clay (58 shared papers)Takuya Osada (61 shared papers)Amy Hobeika (68 shared papers)Herbert I. Hurwitz (56 shared papers)Michael J. Overman (13 shared papers)Bryan M. Clary (24 shared papers)Scott Kopetz (12 shared papers)
- Journals
- Journal of Clinical Oncology (75 papers)Clinical Cancer Research (11 papers)International Journal of Radiation Oncology*Biology*Physics (11 papers)Annals of Oncology (10 papers)Expert Opinion on Biological Therapy (10 papers)
- Partner nations
- United StatesItalyGermany
In The Last Decade
Michael A. Morse
372 papers receiving 17.9k citations
Michael A. Morse's Hit Papers
Peers
Comparison fields: 5 of 135
- Oncology 8.3k
- Immunology 5.5k
- Hepatology 1.1k
- Cancer Research 1.9k
- Pathology and Forensic Medicine 1.4k
Countries citing papers authored by Michael A. Morse
This map shows the geographic impact of Michael A. Morse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Morse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Morse more than expected).
Fields of papers citing papers by Michael A. Morse
This network shows the impact of papers produced by Michael A. Morse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Morse. The network helps show where Michael A. Morse may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael A. Morse, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 382 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study Hit paper breakdown → | 2017 | 2014 |
| 2 | Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose Hit paper breakdown → | 2008 | 1085 |
| 3 | A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer Hit paper breakdown → | 2005 | 929 |
| 4 | Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial Hit paper breakdown → | 2016 | 517 |
| 5 | The Role of Angiogenesis in Hepatocellular Carcinoma Hit paper breakdown → | 2018 | 428 |
| 6 | 2009 | 418 | |
| 7 | 2007 | 298 | |
| 8 | Migration of human dendritic cells after injection in patients with metastatic malignancies. | 1999 | 298 |
| 9 | 2003 | 297 | |
| 10 | Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians Hit paper breakdown → | 2022 | 288 |
| 11 | 2008 | 257 | |
| 12 | 2008 | 244 | |
| 13 | A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. | 1999 | 243 |
| 14 | 2011 | 223 | |
| 15 | 2019 | 180 | |
| 16 | 2007 | 172 | |
| 17 | 2021 | 167 | |
| 18 | 2002 | 162 | |
| 19 | 2011 | 157 | |
| 20 | 2015 | 154 |
About Michael A. Morse
Michael A. Morse is a scholar working on Oncology, Immunology, Molecular Biology, Surgery and Pulmonary and Respiratory Medicine, having authored 382 papers that have together received 18.3k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (118 papers), Cancer Immunotherapy and Biomarkers (78 papers), Colorectal Cancer Treatments and Studies (38 papers), vaccines and immunoinformatics approaches (31 papers), Immune Cell Function and Interaction (30 papers), CAR-T cell therapy research (29 papers), T-cell and B-cell Immunology (25 papers) and Monoclonal and Polyclonal Antibodies Research (23 papers). The work is most often cited by research in Oncology (8.3k citations), Immunology (5.5k citations), Hepatology (1.1k citations), Cancer Research (1.9k citations) and Pathology and Forensic Medicine (1.4k citations). Michael A. Morse has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include H. Kim Lyerly, Timothy M. Clay, Takuya Osada, Amy Hobeika, Herbert I. Hurwitz, Michael J. Overman, Bryan M. Clary, Scott Kopetz, Thierry André and Sara Lonardi. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, International Journal of Radiation Oncology*Biology*Physics, Annals of Oncology and Expert Opinion on Biological Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.